Applikon Bio provides bioprocess equipment and automation solutions for biotechnology research and production

Applikon Bio

Boehringer Ingelheim is involved in research, development, manufacturing, and marketing of pharmaceuticals. self-described.

Boehringer Ingelheim

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain demand-led clinical supply services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. Catalent, Inc. was incorporated in 2007 and is headquartered in Somerset, New Jersey.

Catalent, Inc.

Corning Incorporated engages in display technologies, optical communications, environmental technologies, specialty materials, and life sciences businesses worldwide. The company's Display Technologies segment offers glass substrates for liquid crystal displays and organic light-emitting diodes used in televisions, notebook computers, desktop monitors, tablets, and handheld devices. Its Optical Communications segment provides optical fibers and cables; and hardware and equipment products, including cable assemblies, fiber optic hardware and connectors, optical components and couplers, closures, network interface devices, and other accessories. This segment also offers its products to businesses, governments, and individuals. Its Specialty Materials segment manufactures products that provide material formulations for glass, glass ceramics, crystals, precision metrology instruments, software; as well as ultra-thin and ultra-flat glass wafers, substrates, tinted sunglasses, and radiation shielding products. This segment serves various industries, including mobile consumer electronics, semiconductor equipment optics and consumables; aerospace and defense optics; radiation shielding products, sunglasses, and telecommunications components. The company's Environmental Technologies segment offers ceramic substrates and filter products for emissions control in mobile, gasoline, and diesel applications. The company's Life Sciences segment offers laboratory products comprising consumables, such as plastic vessels, liquid handling plastics, specialty surfaces, cell culture media, and serum, as well as general labware and equipment under the Corning, Falcon, Pyrex, and Axygen brands. The company was formerly known as Corning Glass Works and changed its name to Corning Incorporated in April 1989. Corning Incorporated was founded in 1851 and is headquartered in Corning, New York.

Hao Dong

Amory Houghton

Corning Incorporated

Medical Equipment Manufacturing

Getinge

Applikon Biotechnology | 10,671 followers on LinkedIn. Applikon Biotechnology, part of Getinge since January 2020, is a world leader in developing, manufacturing and supplying bioreactor systems for both research and production use. With the stability that Applikon has shown you can rest assured of dependable service and support in the future. Starting in 1973 Applikon has grown from a small sized company supplying laboratory instrumentation to a dynamic worldwide enterprise capable of supplying a broad and diverse line of bioreactor systems.

Director Product Marketing

Timo Keijzer

Managing CFP's, Production startup, no nonsense production and solution driven flow chain. Continues improvement, follow the dots, synergy of people…

Rizah Robin

Scientific Instruments,Biotechnology Equipment and R&D Solutions 法比奥 卡驰拓.-科学仪器专家

Fabio Cacchiata

Gemeenteraadslid GroenLinks Rijswijk & Customer service representative Getinge Applikon

Lara Oude Alink

Applikon Biotechnology

The time has come to say goodbye to our social media channels. We are all wishing you a happy holiday season and are looking forward to welcome you again on our Getinge social media channels in 2022! #hellogoodbye #socialmedia

Metric
Company Name	Applikon Bio	Boehringer Ingelheim	Catalent, Inc.	Corning Incorporated
Symbol			CTLT	GLW
MSH ID	COM:APPLIKONBIO	COM:BOEHRINGER-INGELHEIM	COM:CATALENT	COM:CORNING
Market	PRIVATE	PRIVATE	STOCKS	STOCKS
Sector	Healthcare & Health Services	Healthcare & Health Services	Healthcare	Technology
Industry	Biotechnology Equipment	Pharmaceuticals	Drug Manufacturers - Specialty & Generic	Hardware, Equipment & Parts
Country	NL	DE	US	US
Stage
Employee Count			18K	49.80K
Website	applikonbio.com	boehringer-ingelheim.com	catalent.com	corning.com
LinkedIn	applikon-biotechnology	boehringer-ingelheim
Founders

Metric
Market Cap	10.39B	38.96B
Enterprise Value
Monthly Web Traffic	215.31K	573.15K
Web Traffic Growth	0.22	-0.20
Valuation
Raised Capital		204M

Metric
Revenue	4.38B	12.59B
Revenue (LTM)
Revenue (NTM)
Gross Profit	953M	3.93B
EBITDA	634M	890M
Operating Income	145M	890M
Net Income	-1.04B	581M
EPS	-5.76	0.69
Diluted EPS	-5.76	0.68
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.22	0.32
Operating Profit Margin	-0.14	0.07
EBITDA Margin	0.14	0.07
Net Profit Margin	-0.23	0.07
Return on Equity	-0.27	0.07
Return on Assets	-0.10	0.03
Return on Capital Employed	-0.07	0.04

COM:APPLIKONBIO

Applikon Bio

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-11.39	33.43
P/B Ratio	2.76	2.36
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	2.61	3.24
EV Multiple	88.01	27.33

Metric
Days Sales Outstanding	71.17	45.58
Days Payables Outstanding	41.18	61.81
Days Inventory Outstanding	84.59	116.99
Operating Cycle	208.07	166.47
Cash Conversion Cycle	166.77	103.18
Asset Turnover	0.45	0.46

Metric
Operating Cash Flow	268M	2.00B
Free Cash Flow	268M	615M
Cash Flow to Debt	0.06	0.29
Operating Cash Flow/Sales	0.06	0.17
Free Cash Flow Yield	-0.02	0.03

Metric
Cash & Equivalents	289M	1.78B
Accounts Receivable		50M
Inventory	574M	2.67B
Goodwill		2.38B
Debt to Capitalization	0.58	0.42
Debt to Assets	0.49	0.26
Current Ratio	1.71	1.67
Quick Ratio	1.96	1.02

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.01	0.01
R&D to Revenue		0.09
SG&A to Revenue